Table 5.
Subgroup analysis in BCAA+ and BCAA− patients.
| Parameter (mean ± SD) | Pretreatment | After TACE | |||
|---|---|---|---|---|---|
| 1 week | 4 weeks | 12 weeks | |||
| BCAA+ (N = 28) | CP score | 6.14 ± 1.04 | 6.43 ± 0.99 | 6.04 ± 1.03‡∗ | 6.24 ± 1.36 |
| S. albumin (g/dL) | 3.18 ± 0.56 | 2.90 ± 0.48†∗∗∗ | 3.25 ± 0.53‡∗∗∗ | 3.10 ± 0.49‡∗ | |
| PT (%) | 87.32 ± 18.99 | 88.50 ± 17.69 | 91.59 ± 18.19 | 88.13 ± 16.96 | |
| T. bilirubin (mg/dL) | 1.05 ± 0.59 | 1.10 ± 0.58 | 1.00 ± 0.56 | 1.22 ± 0.72 | |
| ALT (IU/L) | 37.07 ± 16.50 | 48.68 ± 24.95†∗ | 35.89 ± 15.43‡∗∗ | 37.16 ± 11.05‡∗ | |
| AST (IU/L) | 52.04 ± 22.97 | 48.93 ± 24.65 | 50.79 ± 19.39 | 53.20 ± 18.43 | |
| GGTP (IU/L) | 69.89 ± 72.74 | 86.36 ± 100.41†∗ | 89.26 ± 82.77 | 53.16 ± 36.19§∗ | |
|
| |||||
| BCAA− group (N = 22) | CP score | 5.73 ± 0.93 | 5.90 ± 0.83 | 5.73 ± 0.76 | 6.05 ± 1.23 |
| S. albumin (g/dL) | 3.41 ± 0.55 | 3.12 ± 0.56†∗∗∗ | 3.38 ± 0.61‡∗∗ | 3.40 ± 0.60‡∗ | |
| PT (%) | 88.9 ± 17.2 | 88.8 ± 18.2 | 89.5 ± 16.5 | 89.9 ± 18.0 | |
| T. bilirubin (mg/dL) | 0.88 ± 0.38 | 0.99 ± 0.46 | 0.89 ± 0.43 | 1.02 ± 0.58 | |
| ALT (IU/L) | 37.86 ± 32.04 | 49.81 ± 32.60 | 38.00 ± 26.65 | 34.15 ± 20.24 | |
| AST (IU/L) | 57.36 ± 42.03 | 52.62 ± 34.73 | 60.27 ± 38.91 | 57.25 ± 46.66 | |
| GGTP (IU/L) | 66.59 ± 76.06 | 90.05 ± 127.71 | 100.82 ± 154.50 | 70.50 ± 82.04 | |
SD: standard deviation; CP: Child-Pugh; S. albumin: serum albumin; PT: prothrombin time; T. bilirubin: total bilirubin; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGTP: gamma-glutamyl transpeptidase; TACE: transarterial chemoembolization.
†Significant difference compared with baseline value; ‡significant difference compared with 1 week after TACE; §significant difference compared with 4 weeks after TACE; ∗ P < 0.05; ∗∗ P < 0.01; ∗∗∗ P < 0.001.